Overview

Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

Status:
RECRUITING
Trial end date:
2026-11-07
Target enrollment:
Participant gender:
Summary
A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).
Phase:
PHASE2
Details
Lead Sponsor:
Keymed Biosciences Co.Ltd